Rockwell Medical Technologies Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2009. The company reported third quarter 2009 sales of $14.2 million, up 4.6% from $13.5 million in the third quarter of 2008. Loss for the third quarter 2009 was $1.5 million or $0.11 loss per diluted share compared to $2.5 million or $0.18 loss per diluted share for the third quarter of 2008. Operating loss was $1.5 million against $2.5 million for the same period in 2008. For the first nine months, the company reported sales of $40.0 million increased $1.8 million or 4.8% compared to $38.2 million in the first nine months of 2008. Loss was $4.9 million, or $0.35 loss per diluted share compared to $4.8 million or $0.35 loss per diluted share for the same period of 2008. Operating loss was $4.9 million against $5.0 million for the same period in 2008.

Rockwell Medical Technologies Inc. announced that the last patient has completed the Phase IIb clinical study to investigate Soluble Ferric Pyrophosphate (SFP), the Company's proprietary investigational iron maintenance therapy. The Phase IIb, double-blinded, randomized, placebo-controlled, 6-month duration, dose ranging study enrolled patients at 29 sites in the U.S. and Canada. 131 ESRD patients receiving chronic hemodialysis were dosed at 0, 5, 10, 12, or 15 ug of SFP-derived iron per deciliter of dialysate. The objective of the study was to evaluate the safety of SFP at varying dose levels and to determine the optimal concentration of SFP for maintenance of hemoglobin in the target range by maintaining iron balance. Two Data Safety Monitoring Board reviews of interim study data did not identify any safety concerns nor necessitate any change in the study design or conduct, and the study advanced until the targeted patient enrollment was achieved.

Rockwell Medical Technologies Inc., Q3 2009 Earnings Call, Nov-04-2009